<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57092">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997333</url>
  </required_header>
  <id_info>
    <org_study_id>CDX011-04</org_study_id>
    <nct_id>NCT01997333</nct_id>
  </id_info>
  <brief_title>Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer</brief_title>
  <acronym>METRIC</acronym>
  <official_title>A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Australia: Department of Health and Aging Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
      antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
      Breast Cancer (TNBC; i.e., tumors lacking expression of estrogen, progesterone and HER2
      receptors), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which
      CDX-011 binds to.  The study will also further characterize the safety of CDX-011 treatment
      in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CDX-011 consists of an antibody attached to a drug, monomethyl auristatin E (MMAE), that can
      kill cancer cells. The antibody delivers the drug to cancer cells by attaching to a protein
      called glycoprotein NMB (gpNMB) that is expressed on the cancer cell. The MMAE is then
      released inside of the cell, where it interferes with cell growth and may lead to cell
      death.

      This study will examine the effectiveness and safety of CDX-011 in patients with advanced
      TNBC that makes the gpNMB protein.   The effect of CDX-011 will be compared to treatment
      with capecitabine.

      Eligible patients who enroll in the study will be randomly assigned (by chance) to receive
      treatment with CDX-011 or with capecitabine. For every three patients enrolled, two will
      receive CDX-011 and one will receive treatment with capecitabine.  All patients enrolled in
      the study will be closely monitored to determine if their cancer is responding to treatment
      and for any side effects that may occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Six  weeks following treatment initiation.</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is defined as the proportion of patients who achieve best overall response of complete or partial response according to RECIST 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At least 18 months following treatment initiation.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response  (DOR)</measure>
    <time_frame>At least 18 months following treatment initiation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>During treatment and 3 months from end of treatment through end of study or approximately up to 5 years.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or capecitabine and until discontinuation of follow-up)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK)</measure>
    <time_frame>Following 1 dose of CDX-011.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Concentration of the antibody-drug conjugate, total antibody and free MMAE will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug:  CDX-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-011</intervention_name>
    <arm_group_label>Drug:  CDX-011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Among other criteria, patients must meet all of the following conditions to be eligible
        for the study:

          1. Diagnosed with metastatic (i.e., cancer that has spread) triple negative (does not
             have hormone receptors ER or PR or HER2) breast cancer.

          2. Breast cancer tumor confirmed to express gpNMB. This will be determined by submitting
             a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease
             setting to a central laboratory for analysis.

          3. Received no more than two prior chemotherapy treatments for advanced (locally
             advanced/recurrent or metastatic) breast cancer.

          4. Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin
             or Doxil) and a taxane (eg: Taxol).

          5. Breast cancer must be resistant or intolerant to treatment containing taxane (e.g.
             Taxol).

          6. ECOG performance status of 0 - 1.

          7. Adequate bone marrow, liver and renal function.

        Exclusion:

        Among other criteria, patients who meet any of the following conditions are NOT eligible
        for the study:

          1. Progression/recurrence of breast cancer during or within 6 months of completion of
             neoadjuvant or adjuvant chemotherapy.

          2. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are
             moderate (Grade 2) or worse in severity.

          3. Known brain metastases, unless previously treated and asymptomatic for 2 months and
             not progressive in size or number for 2 months.

          4. Significant cardiovascular disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristie Stricker</last_name>
      <phone>205-786-6983</phone>
    </contact>
    <investigator>
      <last_name>Katisha Vance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Carter</last_name>
      <phone>251-607-5283</phone>
    </contact>
    <investigator>
      <last_name>Thaddeus Beeker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Noboa</last_name>
      <phone>602-938-2848</phone>
    </contact>
    <investigator>
      <last_name>Clarence Adoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Research Alliance</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary High</last_name>
      <phone>480-945-6896</phone>
    </contact>
    <investigator>
      <last_name>Steven Finkelstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niyuri Fleming</last_name>
      <phone>520-694-9079</phone>
    </contact>
    <investigator>
      <last_name>Alison Stopeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Torres</last_name>
      <phone>714-446-5642</phone>
    </contact>
    <investigator>
      <last_name>William Lawler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>La Verne</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Norton</last_name>
      <phone>909-596-5333</phone>
    </contact>
    <investigator>
      <last_name>Misagh Karimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Associates</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sulema Murillo</last_name>
      <phone>323-724-8769</phone>
    </contact>
    <investigator>
      <last_name>John Thropay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Medical Group of Orange Country, Inc.</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Taylor</last_name>
      <phone>714-835-1800</phone>
    </contact>
    <investigator>
      <last_name>Timothy Byun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courney Wells</last_name>
      <phone>916-734-3758</phone>
    </contact>
    <investigator>
      <last_name>Helen Chew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Salinas/Monterey</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Castillo</last_name>
      <phone>831-755-1701</phone>
      <phone_ext>124</phone_ext>
    </contact>
    <investigator>
      <last_name>Laura Stampleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Interactive Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Free</last_name>
      <phone>805-595-3231</phone>
    </contact>
    <investigator>
      <last_name>Brian DiCarlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellness Hematology Oncology</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marylen Roldan</last_name>
      <phone>424-208-8866</phone>
    </contact>
    <investigator>
      <last_name>Ashkan Lashkari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Central Connecticut</name>
      <address>
        <city>Southington</city>
        <state>Connecticut</state>
        <zip>06489</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Turney</last_name>
      <phone>860-621-9316</phone>
    </contact>
    <investigator>
      <last_name>Peter Byeff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Michell</last_name>
      <phone>954-698-3693</phone>
    </contact>
    <investigator>
      <last_name>Charles Vogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayme Ion</last_name>
      <phone>954-265-2615</phone>
    </contact>
    <investigator>
      <last_name>Carmen Calfa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Richmond</last_name>
      <phone>904-202-7070</phone>
    </contact>
    <investigator>
      <last_name>Troy Guthrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Biermeier</last_name>
      <phone>727-216-1143</phone>
      <phone_ext>3081</phone_ext>
    </contact>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists South</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Okeefe</last_name>
      <phone>239-274-9930</phone>
    </contact>
    <investigator>
      <last_name>Lowell Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Martin</last_name>
      <phone>770-496-9420</phone>
    </contact>
    <investigator>
      <last_name>Mansoor Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy McIntosh</last_name>
      <phone>678-298-3259</phone>
    </contact>
    <investigator>
      <last_name>Charles Henderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gilley</last_name>
      <phone>770-281-5131</phone>
    </contact>
    <investigator>
      <last_name>Robert Hermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Care, PC-Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Powell</last_name>
      <phone>912-651-5771</phone>
    </contact>
    <investigator>
      <last_name>Mark Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Eisen</last_name>
      <phone>773-834-1758</phone>
    </contact>
    <investigator>
      <last_name>Rita Nanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalis Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Marriott</last_name>
      <phone>708-915-6119</phone>
    </contact>
    <investigator>
      <last_name>Alexandar Starr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>60615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashton Hitchcock</last_name>
      <phone>309-243-3611</phone>
    </contact>
    <investigator>
      <last_name>Madhuri Bajaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward H. Kaplan and Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Weller</last_name>
      <phone>847-675-3900</phone>
    </contact>
    <investigator>
      <last_name>Edward H Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc.</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Jardinico</last_name>
      <phone>224-534-7580</phone>
    </contact>
    <investigator>
      <last_name>Ira Oliff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Canfield</last_name>
      <phone>217-383-6828</phone>
    </contact>
    <investigator>
      <last_name>Kendrith Rowland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Doligosa</last_name>
      <phone>847-872-4019</phone>
    </contact>
    <investigator>
      <last_name>Dennis Citrin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Valley Medical Specialists</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Waltztoni</last_name>
      <phone>319-233-2701</phone>
    </contact>
    <investigator>
      <last_name>Joginder Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Specialists</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ann Ostroske</last_name>
      <phone>504-885-8220</phone>
    </contact>
    <investigator>
      <last_name>Milton Seiler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shebna Garcon</last_name>
      <phone>301-754-8556</phone>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Vallieres</last_name>
      <phone>313-916-2438</phone>
    </contact>
    <investigator>
      <last_name>Randa Loutfi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Hematology and Oncology Associates</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marthe Thomas</last_name>
      <phone>662-407-4090</phone>
    </contact>
    <investigator>
      <last_name>Chris Croot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Maher</last_name>
      <phone>573-893-2375</phone>
    </contact>
    <investigator>
      <last_name>Ali Khojasteh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St John's Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Tindall</last_name>
      <phone>314-251-7060</phone>
    </contact>
    <investigator>
      <last_name>Bethany Sleckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Frydenlund</last_name>
      <phone>406-329-0349</phone>
    </contact>
    <investigator>
      <last_name>Patrick Beatty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Smith</last_name>
      <phone>402-991-8070</phone>
      <phone_ext>201</phone_ext>
    </contact>
    <investigator>
      <last_name>Gamini Soori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProHEALTH Care Associates</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Grogan</last_name>
      <phone>516-622-6150</phone>
    </contact>
    <investigator>
      <last_name>Marc Citron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance, Inc.</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany McLaughlin</last_name>
      <phone>516-488-2918</phone>
    </contact>
    <investigator>
      <last_name>Morton Coleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Oncology Specialists PA</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Gray</last_name>
      <phone>828-324-9550</phone>
      <phone_ext>230</phone_ext>
    </contact>
    <investigator>
      <last_name>Richard Orlowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Given</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27110</phone_ext>
    </contact>
    <investigator>
      <last_name>Patrick Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center, LLC</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Wenning</last_name>
      <phone>513-423-0504</phone>
    </contact>
    <investigator>
      <last_name>Nandagopal Vrindavanam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Caldwell</last_name>
      <phone>405-751-4343</phone>
    </contact>
    <investigator>
      <last_name>Vikki Canfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Hospital</name>
      <address>
        <city>Coos Bay</city>
        <state>Oregon</state>
        <zip>97420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Cox, 541-269-8392</last_name>
      <phone>541-269-8392</phone>
    </contact>
    <investigator>
      <last_name>Bret Cook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Torres</last_name>
      <phone>215-710-4594</phone>
    </contact>
    <investigator>
      <last_name>Robert Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guthrie Clinical Research</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hadlock</last_name>
      <phone>570-887-2141</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology Oncology Associates (CHOA)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah McNeal</last_name>
      <phone>843-266-2540</phone>
    </contact>
    <investigator>
      <last_name>David Ellison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Parker</last_name>
      <phone>423-698-1844</phone>
    </contact>
    <investigator>
      <last_name>Brooke Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gena Bagwell</last_name>
      <phone>423-622-2337</phone>
    </contact>
    <investigator>
      <last_name>Jitendra Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jones Clinic, PC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Lynch</last_name>
      <phone>901-685-5969</phone>
    </contact>
    <investigator>
      <last_name>Clyde Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Sherrill</last_name>
      <phone>615-524-4240</phone>
    </contact>
    <investigator>
      <last_name>Denise Yardley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Consultants PA</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sottosanti</last_name>
      <phone>817-759-7023</phone>
    </contact>
    <investigator>
      <last_name>Robyn Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Montez</last_name>
      <phone>612 9355 5614</phone>
    </contact>
    <investigator>
      <last_name>Richard Epstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Dunne</last_name>
      <phone>61 75506 7374</phone>
    </contact>
    <investigator>
      <last_name>Ehtesham Abdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Page</last_name>
      <phone>07 4433 3548</phone>
    </contact>
    <investigator>
      <last_name>Abhishek Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Rainford</last_name>
      <phone>61 3834 56 208</phone>
    </contact>
    <investigator>
      <last_name>Catherine Oakman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth Health Care</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendie Hopkins</last_name>
      <phone>613 9936 8206</phone>
    </contact>
    <investigator>
      <last_name>Ross Jennens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program Sault Area Hospital</name>
      <address>
        <city>Sault Ste Marie</city>
        <state>Ontario</state>
        <zip>P6B-0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Kovacevich</last_name>
      <phone>705 759 3434</phone>
      <phone_ext>4241</phone_ext>
    </contact>
    <investigator>
      <last_name>Silvana Spadafora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Locally advanced breast cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Triple negative</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Progesterone</keyword>
  <keyword>HER2 receptors</keyword>
  <keyword>Targeted treatment for breast cancer</keyword>
  <keyword>Antibody-drug-conjugate</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>CDX-011</keyword>
  <keyword>gpNMB</keyword>
  <keyword>METRIC</keyword>
  <keyword>Glembatumumab vedotin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
